公开(公告)号：US20240350607A1

公开(公告)日：2024-10-24

申请号：US18687463

申请日：2022-08-30

Applicant: Vir Biotechnology, Inc.

Inventor： Ann M. Arvin ,  Julia Di Iulio ,  Janet L. Douglas ,  Emily Marshall ,  Leah B. Soriaga ,  Herbert W. Virgin

IPC: A61K39/04 ,  A61K39/00 ,  C07K14/35 ,  C12N5/0783 ,  C12N15/86

CPC classification number: A61K39/04 ,  A61K39/4611 ,  C07K14/35 ,  C12N5/0636 ,  C12N15/86 ,  A61K2039/5256 ,  C07K2319/42 ,  C12N2510/00 ,  C12N2710/16143

Abstract: The disclosure relates to tuberculosis antigens and vectors for delivering the antigens. The disclosure also relates to immunogenic compositions comprising the same, and their uses.

公开(公告)号：US12097244B2

公开(公告)日：2024-09-24

申请号：US18394409

申请日：2023-12-22

Applicant: Altor Bioscience, LLC

Inventor： Bai Liu ,  Peter Rhode ,  Wenxin Xu ,  Hing C. Wong

IPC: A61K39/395 ,  A61K38/17 ,  A61K38/20 ,  A61K47/64 ,  A61P35/00 ,  A61K39/04 ,  C07K14/35 ,  C07K14/54 ,  C07K14/715 ,  C07K16/28 ,  C07K16/32

CPC classification number: A61K38/2086 ,  A61K38/1793 ,  A61K39/39558 ,  A61K47/6425 ,  A61P35/00 ,  A61K39/04 ,  C07K14/35 ,  C07K14/5443 ,  C07K14/7155 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/32 ,  C07K2317/732 ,  C07K2319/30 ,  C07K2319/32

Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.

公开(公告)号：US20240307494A1

公开(公告)日：2024-09-19

申请号：US18737455

申请日：2024-06-07

Applicant: Altor Bioscience, LLC

Inventor： Bai Liu ,  Peter Rhode ,  Wenxin Xu ,  Hing C. Wong

IPC: A61K38/20 ,  A61K38/17 ,  A61K39/04 ,  A61K39/395 ,  A61K47/64 ,  A61P35/00 ,  C07K14/35 ,  C07K14/54 ,  C07K14/715 ,  C07K16/28 ,  C07K16/32

CPC classification number: A61K38/2086 ,  A61K38/1793 ,  A61K39/39558 ,  A61K47/6425 ,  A61P35/00 ,  A61K39/04 ,  C07K14/35 ,  C07K14/5443 ,  C07K14/7155 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/32 ,  C07K2317/732 ,  C07K2319/30 ,  C07K2319/32

Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.

公开(公告)号：US20240287487A1

公开(公告)日：2024-08-29

申请号：US18568796

申请日：2022-06-10

Applicant: The Broad Institute, Inc. ,  President and Fellows of Harvard College ,  The Regents of the University of California ,  Massachusetts Institute of Technology

Inventor： Luke W. Koblan ,  David R. Liu ,  Mandana Arbab ,  Max Walt Shen ,  Andrew Vito Anzalone ,  Jeffrey Hussmann

IPC: C12N9/22 ,  A61K38/00 ,  C07K14/35 ,  C12N9/10 ,  C12N9/12 ,  C12N9/78 ,  C12N15/11 ,  C12N15/90

CPC classification number: C12N9/22 ,  C07K14/35 ,  C12N9/104 ,  C12N9/1252 ,  C12N9/78 ,  C12N15/11 ,  C12N15/907 ,  C12Y207/07007 ,  C12Y305/04005 ,  A61K38/00 ,  C07K2319/00 ,  C12N2310/20 ,  C12N2800/80

Abstract: Aspects of this disclosure provide compositions, strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. Fusion proteins capable of inducing a cytosine (C) to guanine (G) change (i.e., transversion changes) in a nucleic acid (e.g., genomic DNA) are provided. Fusion proteins of a nucleic acid programmable DNA binding protein (e.g., Cas9) and nucleic acid editing proteins or protein domains, e.g., deaminase domains, polymerase domains, base excision enzymes, and/or DNA repair proteins, are also provided. Methods for targeted nucleic acid editing are also provided. Reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of a nucleic acid programmable DNA binding protein (e.g., Cas9), and nucleic acid editing proteins or domains, are further provided in the present disclosure.

公开(公告)号：US20240252591A1

公开(公告)日：2024-08-01

申请号：US18639678

申请日：2024-04-18

Applicant: Altor Bioscience, LLC

Inventor： Bai Liu ,  Peter Rhode ,  Wenxin Xu ,  Hing C. Wong

IPC: A61K38/20 ,  A61K38/17 ,  A61K39/04 ,  A61K39/395 ,  A61K47/64 ,  A61P35/00 ,  C07K14/35 ,  C07K14/54 ,  C07K14/715 ,  C07K16/28 ,  C07K16/32

CPC classification number: A61K38/2086 ,  A61K38/1793 ,  A61K39/39558 ,  A61K47/6425 ,  A61P35/00 ,  A61K39/04 ,  C07K14/35 ,  C07K14/5443 ,  C07K14/7155 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/32 ,  C07K2317/732 ,  C07K2319/30 ,  C07K2319/32

Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.

公开(公告)号：US11963519B2

公开(公告)日：2024-04-23

申请号：US17895405

申请日：2022-08-25

Applicant: Northwest Institute of Plateau Biology, CAS

Inventor： Cen Li ,  Hongxia Yang ,  Jing Zhao ,  Lixin Wei ,  Yuzhi Du ,  Yuancan Xiao ,  Hongtao Bi ,  Zhanjuan Chen ,  Yajun Qiao ,  Jianv Wang

IPC: A01K67/02 ,  C07K14/235 ,  C07K14/35

CPC classification number: A01K67/02 ,  C07K14/235 ,  C07K14/35 ,  A01K2227/105 ,  A01K2267/0356

Abstract: The present disclosure provides a kit and method for constructing a long-acting depression animal model. The present disclosure adopts Bacille Calmette-Guerin (BCG) (or Mycobacterium bovis (M bovis)) and low-dose pertussis toxin (PTX) for combined induction, which greatly reduces modeling cost. A mouse model constructed by the method of the present disclosure can clearly distinguish a time interval of pathological behaviors from a time interval of depression-like behaviors and has prominent face validity and predictive validity. The method of the present disclosure is simple and convenient and does not require a large number of tedious daily operations as the depression model construction by chronic unpredictable stress, chronic restraint stress, social defeat, mother-child separation, or the like. The mouse model of the present disclosure can provide a valuable long-term intervention window for research on antidepressant therapy.

公开(公告)号：US20240009288A1

公开(公告)日：2024-01-11

申请号：US18349678

申请日：2023-07-10

Applicant: City of Hope

Inventor： Xiuli Wang ,  Stephen J. Forman

IPC: A61K39/00 ,  C07K14/705 ,  C07K14/35 ,  A61K35/17 ,  C07K16/28 ,  C07K14/725 ,  C07K14/71 ,  C12N5/0783

CPC classification number: A61K39/0011 ,  C07K14/705 ,  C07K14/35 ,  A61K35/17 ,  C07K16/2803 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/71 ,  C07K16/2896 ,  C12N5/0636 ,  C12N5/0637 ,  C12N5/0638 ,  C07K2319/02 ,  C07K2319/03 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K2317/622 ,  C07K2319/033 ,  C07K2317/526 ,  C07K2317/53 ,  C12N2510/00

Abstract: Chimeric antigen receptors for use in treating malignant melanoma and other cancers expressing CS1 are described.

公开(公告)号：US11858966B2

公开(公告)日：2024-01-02

申请号：US17674140

申请日：2022-02-17

Applicant: THE UAB RESEARCH FOUNDATION

Inventor： Michael Niederweis ,  Mikhail Pavlenok

IPC: C07H21/04 ,  C07K14/35 ,  C12Q1/6869 ,  G01N27/447 ,  G01N33/487

CPC classification number: C07K14/35 ,  C12Q1/6869 ,  G01N27/44743 ,  G01N27/44756 ,  G01N33/48721

Abstract: Provided herein are mutant single-chain Mycobacterium smegmatis porin (Msp) and uses thereof.

公开(公告)号：US11739377B2

公开(公告)日：2023-08-29

申请号：US17075017

申请日：2020-10-20

Applicant: Oxford Nanopore Technologies PLC

Inventor： Lakmal Nishantha Jayasinghe ,  Elizabeth Jayne Wallace ,  Jonathan Bankes Pugh ,  Richard George Hambley ,  Neil Roger Wood ,  Clive Gavin Brown ,  James White ,  Andrew John Heron ,  Mark Bruce ,  Christopher Peter Youd ,  Rebecca Victoria Bowen

IPC: C07K14/35 ,  C12Q1/68 ,  C12Q1/6869

CPC classification number: C12Q1/6869 ,  C07K14/35 ,  C12Q1/6869 ,  C12Q2563/157 ,  C12Q2565/631

Abstract: The invention relates to improving the movement of a target polynucleotide with respect to a transmembrane pore when the movement is controlled by a polynucleotide binding protein. The invention also relates to improved transmembrane pores and polynucleotide binding proteins.

公开(公告)号：US20230203107A1

公开(公告)日：2023-06-29

申请号：US18053965

申请日：2022-11-09

Applicant: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS

Inventor： Chul Su YANG ,  Da Eun LEE

IPC: C07K14/35 ,  A61P31/04 ,  A61P37/06

CPC classification number: C07K14/35 ,  A61P31/04 ,  A61P37/06 ,  A61K38/00

Abstract: Provided is an Rv3364c-derived peptide capable of directly binding to a BAR domain of SNX9. The Rv3364c-derived peptide of the present disclosure may regulate a TLR4-mediated inflammatory response depending on SNX9, and thus can be effectively applied to not only the use for the prevention and treatment of Mycobacterium tuberculosis infectious disease, but also the use for the prevention and treatment of sepsis and sepsis shock.